Eikon Therapeutics
EIKN · Nasdaq · United States
Share price · EIKN
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when EIKN's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 4 Nov 2026+15.1%
Nothing announced by EIKN that day or the session before.
- 26 Oct 2026-23.7%
- 23 Oct 2026-11.9%
- 16 Sep 2026-10.3%
Nothing announced by EIKN that day or the session before.
- 10 Sep 2026-14.2%
Nothing announced by EIKN that day or the session before.
- 25 Aug 2026+12.5%
Nothing announced by EIKN that day or the session before.
- 18 Aug 2026+11.3%
Nothing announced by EIKN that day or the session before.
- 27 Jul 2026+11.0%
- 26 Jun 2026+16.2%
- 12 May 2026+15.9%
Share of unusual movement by asset
For each asset, the share of EIKN's own-move activity since 6 Feb 2026 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2/3 | Toll-like receptor 7 and 8 (TLR7/8)Small molecule | Non-Small Cell Lung CancerMelanoma |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (6)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $72M | $98M+ $363M short-term inv. | $86M-$69M operating cash flow | report ↗ |
View 5 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $75M | $143M+ $389M short-term inv. | $88M-$65M operating cash flow | report ↗ |
| 2026-Q1 | $0 | — | $596M | $83M | report ↗ |
| 2025-Q3 | — | $59M | $105M | $71M-$60M operating cash flow | report ↗ |
| 2025-Q2 | — | $69M | $137M | $105M-$33M operating cash flow | report ↗ |
| 2025-Q1 | — | $57M | $205M | $68M-$55M operating cash flow | report ↗ |
Annual history (1 year)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $0 | $250M | $336M | $324M | report ↗ |
Eikon Therapeutics reported full-year 2025 revenue of $0M, with R&D expenses of $250.3M, up 22% YoY, and cash, cash equivalents, and marketable securities of $336.0M as of December 31, 2025. The company reported a full-year net loss and comprehensive loss of $324.2M and a net loss attributable to common stockholders of $333.6M.
Eikon closed an upsized IPO in February 2026, raising $381.2M in gross proceeds, and expects current cash to fund operations into the second half of 2027. Enrollment was completed in the TeLuRide-005 Phase 2 trial of EIK1001 in first-line non-small cell lung cancer, with a comprehensive data set expected in 2H 2026. EIK1003 and EIK1004 are being evaluated in Phase 1/2 trials, with EIK1003 Cohort 1D initiation anticipated in 2H 2026. EIK1005 had a preclinical abstract accepted at the 2026 AACR annual meeting, and a Phase 1/2 trial is underway following completion of a healthy volunteer study. David W. Meline was elected as an independent director in December 2025.
Insider transactions
Open-market activity, trailing 12 months: 10 purchases ($52.2M), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-09-03 | Column Group IV GP, LP; Column Group IV-A, LP; Column Group IV, LP; Column Group Opportunity III, LP; Column Group Opportunity III GP, LP; TCG Opportunity III GP, LLC; Kutzkey Tim; Svennilson Peter · 10% owner; 10% owner; 10% owner; 10% owner; 10% owner; 10% owner; 10% owner; 10% owner | Open-market purchase | 89,200 | $11.56 | $1.0M | Form 4 |
| 2026-03-02 | Bowie Alfred Lloyd Jr. · Chief Financial Officer | Award / grant (derivative) | 67,044 | — | — | Form 4 |
| 2026-03-02 | Baynes Roy D. · Chief Medical Officer | Award / grant (derivative) | 134,088 | — | — | Form 4 |
| 2026-03-02 | Thorner Benjamin Bruno · See Remarks | Award / grant (derivative) | 67,044 | — | — | Form 4 |
| 2026-03-02 | PERLMUTTER ROGER M · director, See remarks | Award / grant (derivative) | 268,176 | — | — | Form 4 |
| 2026-03-02 | FRAZIER KENNETH C · director | Award / grant (derivative) | 25,873 | — | — | Form 4 |
| 2026-03-02 | Huffines Robert Luther · director | Award / grant (derivative) | 25,873 | — | — | Form 4 |
| 2026-03-02 | Klobuchar Michael A · Chief Operating Officer | Award / grant (derivative) | 87,157 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 52 reporting institutions held 23.7M shares ($228.0M, 43.8% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | FMR LLC | 3,836,830 | $40.6M |
| 2 | BlackRock, Inc. | 3,319,379 | $35.1M |
| 3 | Foresite Capital Management IV, LLC | 1,943,682 | $20.6M |
| 4 | Merck & Co., Inc. | 1,666,666 | $17.6M |
| 5 | Foresite Capital Management V, LLC | 1,318,983 | $14.0M |
| 6 | Capital World Investors | 1,143,637 | $12.1M |
| 7 | ALLIANCEBERNSTEIN L.P. | 1,022,188 | $10.8M |
| 8 | VANGUARD CAPITAL MANAGEMENT LLC | 969,431 | $10.3M |
| 9 | EcoR1 Capital, LLC | 732,606 | $7.8M |
| 10 | BAKER BROS. ADVISORS LP | 555,555 | $5.9M |
| 11 | SOROS CAPITAL MANAGEMENT LLC | 484,672 | $5.1M |
| 12 | StepStone Group LP | 395,340 | $4.2M |
| 13 | CANADA PENSION PLAN INVESTMENT BOARD | 379,024 | $4.0M |
| 14 | FRANKLIN RESOURCES INC | 350,000 | $3.7M |
| 15 | CITADEL ADVISORS LLC | 310,000 | $3.3M |